A New Era of Vaccines
For the Czech Republic

Novavax, Inc. is a global biotechnology company committed to helping address serious infectious diseases globally through the discovery, development, and delivery of innovative vaccines to patients around the world.

Our technology

Our vaccine technology leverages our proprietary recombinant protein-based nanoparticle technology and the immunogenicity-enhancing properties of our Matrix-M™ adjuvant.

Nanoparticles: By organizing recombinant proteins in a nanoparticle, it may help the immune system recognize that target protein from different angles1—the same way that the immune system would see the details of a real pathogen. In our vaccines, there’s no actual virus, just the protein; therefore, these vaccines can't cause disease.

Matrix-M adjuvant: Our Matrix-M adjuvant comes from saponins, naturally occurring compounds in the bark of the Quillaja saponaria (Soapbark) tree, commonly found in Chile. Saponins have a long history of being used for their medicinal properties.2 A vaccine containing another saponin-based adjuvant has previously been approved by the European Medicines Agency (EMA).3

Our areas of research

The world urgently needs new tools to help solve some of our greatest infectious disease challenges. Novavax is applying our unique technology to address current, emerging, and future public health threats. Novavax continually conducts clinical trials, investigations, and gathers real-world evidence in order to develop vaccines to address public health threats. Our scientists in our research and development (R&D) programs are committed to the efficient delivery of new vaccines while maintaining the safety of participants who take part in our trials.

How to contact Novavax
General inquiries

+420 228 880 267
09:00 - 17:00
Monday - Friday

Our location: Líbalova 2348/1, Chodov, 149 00 Prague 4, Czech Republic  

Production site: Bohumil 138, 281 63 Jevany, Czech Republic

Media contact
Investor contact

To contact a member of the investor relations team, click on the "Contact us" button below.

  1. Krueger S, et al. Structural characterization and modeling of a respiratory syncytial virus fusion glycoprotein nanoparticle vaccine in solution. Mol Pharm. 2021;18(1):359–376.
  2. Marciani DJ. Elucidating the mechanisms of action of saponin-derived adjuvants. Trends Pharmacol Sci. 2018;39(6):573-585.
  3. Shingrix. Prescribing information. GSK; 2017.